<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139376">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679782</url>
  </required_header>
  <id_info>
    <org_study_id>FVIE_FA1</org_study_id>
    <nct_id>NCT01679782</nct_id>
  </id_info>
  <brief_title>Involvement of Nervous System in Muscle Weakness in COPD Patients</brief_title>
  <acronym>DesCoM-1</acronym>
  <official_title>Phase 1 Impact of Nocturnal Desaturations on Central Motor Drive in COPD Patients: A New Insight on the Systemic Effects of the Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Fontalvie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M2H laboratory, Montpellier University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANRT, National French Agency for Technological Researches</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Fontalvie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nervous system alterations and motor drive
      failure can contribute to muscle weakness in COPD during voluntary movement. If necessary,
      we will look after the role of nocturnal hypoxia in these alterations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD is a common disease that induces many systemic repercussions. Among these, peripheral
      muscle dysfunction is particularly deleterious because it leads to the decreases of the
      level of activity and the quality of life for patients. Movement involves activation of many
      structures, from the instructor, i.e. the brain, to the effector, i.e. the muscle.
      Netherless, the studies which have described peripheral muscle dysfunction have been focused
      on the muscle, so they have proposed a reducing vision of the phenomenon. Other studies have
      reported cerebral alterations in COPD, like cognitive disturbance, increase of the neuronal
      conduction time, and decrease of the white matter density, and were associated with chronic
      hypoxemia. Such alterations are consistent with the existence of a decrease of the central
      motor drive during voluntary movement in COPD patients. Therefore the study will aim to
      determine precisely which mechanisms are involved in peripheral muscle dysfunction in copd.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD nocturnal desaturator</arm_group_label>
    <description>COPD patients who spend 30% of the nigth with a SaO2 &lt; 90%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD no nocturnal desaturator</arm_group_label>
    <description>COPD patients who spend less than 30% of the night with a SaO2 &lt; 90%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>healthy sedentary subjects</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Two groups of COPD patients and one group with healthy sedentary subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD Patients at stage 2 and 3

          -  Healthy sedentary subjects

        Exclusion Criteria:

          -  Epilepsy, pace-maker, nervous disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain AV Varray, Pr</last_name>
    <role>Study Director</role>
    <affiliation>M2H laboratory, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francois FA Alexandre, PhD student</last_name>
    <phone>0666678916</phone>
    <phone_ext>0033</phone_ext>
    <email>francois.alexandre@fontalvie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain AV Varray, Pr</last_name>
    <phone>0411759070</phone>
    <phone_ext>0033</phone_ext>
    <email>alain.varray@univ-montp1.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique du Souffle La Vallonie</name>
      <address>
        <city>Lodève</city>
        <zip>34700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois FA Alexandre, PhD student</last_name>
      <phone>0666678916</phone>
      <phone_ext>0033</phone_ext>
      <email>francois.alexandre@fontalvie.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 3, 2012</lastchanged_date>
  <firstreceived_date>September 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, nervous system, peripheral muscle dysfunction</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
